ATE272117T1 - Rekombinante zellen der monozyten-makrophagen zelllinie zur gen-therapie - Google Patents
Rekombinante zellen der monozyten-makrophagen zelllinie zur gen-therapieInfo
- Publication number
- ATE272117T1 ATE272117T1 AT94925523T AT94925523T ATE272117T1 AT E272117 T1 ATE272117 T1 AT E272117T1 AT 94925523 T AT94925523 T AT 94925523T AT 94925523 T AT94925523 T AT 94925523T AT E272117 T1 ATE272117 T1 AT E272117T1
- Authority
- AT
- Austria
- Prior art keywords
- monocyte
- cell line
- gene therapy
- recombinant cells
- macrophage cell
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/52—Cytokines; Lymphokines; Interferons
- C07K14/555—Interferons [IFN]
- C07K14/57—IFN-gamma
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/52—Cytokines; Lymphokines; Interferons
- C07K14/525—Tumour necrosis factor [TNF]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Genetics & Genomics (AREA)
- Molecular Biology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Biophysics (AREA)
- Biochemistry (AREA)
- Gastroenterology & Hepatology (AREA)
- Zoology (AREA)
- Toxicology (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Chemical & Material Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Pharmacology & Pharmacy (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
FR9310222A FR2709309B1 (fr) | 1993-08-25 | 1993-08-25 | Compositions cellulaires, préparation et utilisations thérapeutiques. |
PCT/FR1994/001019 WO1995006120A1 (fr) | 1993-08-25 | 1994-08-22 | Cellules recombinantes de la lignee monocyte-macrophage pour la therapie genique |
Publications (1)
Publication Number | Publication Date |
---|---|
ATE272117T1 true ATE272117T1 (de) | 2004-08-15 |
Family
ID=9450378
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
AT94925523T ATE272117T1 (de) | 1993-08-25 | 1994-08-22 | Rekombinante zellen der monozyten-makrophagen zelllinie zur gen-therapie |
Country Status (14)
Country | Link |
---|---|
US (1) | US6210963B1 (de) |
EP (1) | EP0719332B1 (de) |
JP (1) | JP3731035B2 (de) |
KR (1) | KR100392984B1 (de) |
AT (1) | ATE272117T1 (de) |
AU (1) | AU698043B2 (de) |
CA (1) | CA2170159A1 (de) |
DE (1) | DE69433921T2 (de) |
FI (1) | FI960855A (de) |
FR (1) | FR2709309B1 (de) |
IL (1) | IL110754A (de) |
NO (1) | NO319990B1 (de) |
WO (1) | WO1995006120A1 (de) |
ZA (1) | ZA946264B (de) |
Families Citing this family (39)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US6734014B1 (en) | 1996-02-08 | 2004-05-11 | The United States Of America As Represented By The Department Of Health And Human Services | Methods and compositions for transforming dendritic cells and activating T cells |
DE69734974D1 (de) * | 1996-02-08 | 2006-02-02 | Us Gov Health & Human Serv | Verfahren zur transformation dendritischer zellen und aktivierung von t zellen |
FR2746109B1 (fr) | 1996-03-12 | 1998-04-17 | Rhone Poulenc Rorer Sa | Milieu pour la conservation de materiel biologique |
GB2332434B (en) * | 1996-10-09 | 2001-04-04 | Oxford Biomedica Ltd | Mononuclear phagocytes in therapeutic drug delivery |
US20020068048A1 (en) * | 1997-09-05 | 2002-06-06 | Patrick A. Dreyfus | Method for the treatment or diagnosis of human pathologies with disseminated or difficult to access cells or tissues |
NZ503318A (en) * | 1997-09-23 | 2001-11-30 | Oxford Biomedica Ltd | Modified haemopoietic stem cell comprised of a spliced upstream with a nucleotide sequence of interest to be used as in gene therapy |
EP1165754A1 (de) * | 1999-04-06 | 2002-01-02 | Max-Planck-Gesellschaft zur Förderung der Wissenschaften e.V. | Pharmazeutische zusammensetzung enthaltend zirkulierende blutzellen, bevorzugt monocyten, und deren verwendung |
WO2001087314A1 (en) * | 2000-05-18 | 2001-11-22 | Genetix Pharmaceuticals, Inc. | Methods and compositions for promoting angiogenesis using monocytes |
US6579522B1 (en) | 2000-06-27 | 2003-06-17 | Genvec, Inc. | Replication deficient adenoviral TNF vector |
CN1388248A (zh) * | 2001-05-25 | 2003-01-01 | 钱其军 | 高效表达干扰素的肿瘤细胞内特异性增殖的腺病毒及其构建方法 |
AU2002341717A1 (en) * | 2001-09-17 | 2003-04-01 | Medcell Biologics, Llc. | Cell therapy system |
US20030086903A1 (en) | 2001-11-02 | 2003-05-08 | Genvec, Inc. | Therapeutic regimen for treating cancer |
CA2425021A1 (en) * | 2002-04-12 | 2003-10-12 | Sumitomo Electric Industries, Ltd. | Control of the ratio of lap to lip |
WO2004050683A2 (en) * | 2002-12-02 | 2004-06-17 | Abgenix, Inc. | Antibodies directed to tumor necrosis factor and uses thereof |
EP1638587A4 (de) | 2003-02-14 | 2007-04-18 | Univ Missouri | Empfängnisverhütende verfahren und zusammensetzungen betreffend proteasomale störung |
US20080038234A1 (en) * | 2004-03-23 | 2008-02-14 | Shuji Hayashi | Bone Marrow-Related Cells Associated With Tissue Maintenance And/Or Repair |
US7838503B2 (en) * | 2005-06-15 | 2010-11-23 | Children's Medical Center Corporation | Methods for extending the replicative lifespan of cells |
EP2079830B1 (de) | 2006-10-04 | 2016-08-17 | Janssen Pharmaceutica NV | Herstellung von zellen mit deaktivierten künstlichen antigenen und ihre verwendung in zelltherapien |
US8202717B2 (en) | 2007-01-12 | 2012-06-19 | The Board Of Trustees Of The University Of Illinois | Non-simian cells for growth of porcine reproductive and respiratory syndrome (PRRS) virus |
JP5546107B2 (ja) * | 2008-04-17 | 2014-07-09 | 国立大学法人宇都宮大学 | RNAウイルスBmMLV陰性カイコ培養細胞株 |
EP2248903A1 (de) * | 2009-04-29 | 2010-11-10 | Universitat Autònoma De Barcelona | Verfahren und Reagenzien zum effizienten und gezielten Gentransfer in Monozyten und Makrophagen |
AU2011230619C1 (en) | 2010-03-25 | 2016-06-23 | Oregon Health & Science University | CMV glycoproteins and recombinant vectors |
LT2691530T (lt) | 2011-06-10 | 2018-08-10 | Oregon Health & Science University | Cmv glikoproteinai ir rekombinantiniai vektoriai |
US20130189754A1 (en) | 2011-09-12 | 2013-07-25 | International Aids Vaccine Initiative | Immunoselection of recombinant vesicular stomatitis virus expressing hiv-1 proteins by broadly neutralizing antibodies |
US9402894B2 (en) | 2011-10-27 | 2016-08-02 | International Aids Vaccine Initiative | Viral particles derived from an enveloped virus |
EP2679596B1 (de) | 2012-06-27 | 2017-04-12 | International Aids Vaccine Initiative | HIV-1 Env-proteinvariante |
KR20160002971A (ko) | 2013-04-18 | 2016-01-08 | 틸트 바이오세러퓨틱스 오이 | 향상된 입양 세포 치료 |
US20150065381A1 (en) | 2013-09-05 | 2015-03-05 | International Aids Vaccine Initiative | Methods of identifying novel hiv-1 immunogens |
US10058604B2 (en) | 2013-10-07 | 2018-08-28 | International Aids Vaccine Initiative | Soluble HIV-1 envelope glycoprotein trimers |
US20170151281A1 (en) | 2015-02-19 | 2017-06-01 | Batu Biologics, Inc. | Chimeric antigen receptor dendritic cell (car-dc) for treatment of cancer |
US10174292B2 (en) | 2015-03-20 | 2019-01-08 | International Aids Vaccine Initiative | Soluble HIV-1 envelope glycoprotein trimers |
EP3072901A1 (de) | 2015-03-23 | 2016-09-28 | International Aids Vaccine Initiative | Lösliche hiv-1-hüllglykoproteintrimere |
EP3601539A4 (de) * | 2017-03-28 | 2021-01-13 | Zhenglun Zhu | Verfahren zur behandlung von neoplastischen erkrankungen |
WO2020097193A1 (en) | 2018-11-06 | 2020-05-14 | The Regents Of The University Of California | Chimeric antigen receptors for phagocytosis |
US11026973B2 (en) | 2019-04-30 | 2021-06-08 | Myeloid Therapeutics, Inc. | Engineered phagocytic receptor compositions and methods of use thereof |
BR112022003970A2 (pt) | 2019-09-03 | 2022-06-21 | Myeloid Therapeutics Inc | Métodos e composições para integração genômica |
US10980836B1 (en) | 2019-12-11 | 2021-04-20 | Myeloid Therapeutics, Inc. | Therapeutic cell compositions and methods of manufacturing and use thereof |
EP4240367A2 (de) | 2020-11-04 | 2023-09-13 | Myeloid Therapeutics, Inc. | Manipulierte chimäre fusionsproteinzusammensetzungen und verfahren zur verwendung davon |
CN114657143B (zh) * | 2022-03-11 | 2022-10-25 | 西安电子科技大学 | 一种肿瘤微环境调控型car-单核/巨噬细胞及其制备方法和应用 |
Family Cites Families (13)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO1989005349A1 (en) * | 1987-12-09 | 1989-06-15 | The Australian National University | Method of combating viral infections |
US5399493A (en) * | 1989-06-15 | 1995-03-21 | The Regents Of The University Of Michigan | Methods and compositions for the optimization of human hematopoietic progenitor cell cultures |
CA1340565C (en) * | 1989-06-29 | 1999-05-25 | Thomas B. Okarma | Device and process for cell capture and recovery |
US5246921A (en) * | 1990-06-26 | 1993-09-21 | The Wistar Institute Of Anatomy And Biology | Method for treating leukemias |
FR2683725B1 (fr) * | 1991-11-15 | 1995-07-07 | Pasteur Institut | Composition cellulaire pour le traitement des organismes humains ou animaux. |
EP0667792A1 (de) * | 1991-11-22 | 1995-08-23 | The General Hospital Corporation | Spezifische toleranz bei transplantation |
US5338165A (en) * | 1991-11-25 | 1994-08-16 | Ford Motor Company | Automotive fuel pump with modular pump housing |
GB9125623D0 (en) * | 1991-12-02 | 1992-01-29 | Dynal As | Cell modification |
US5436151A (en) * | 1992-04-03 | 1995-07-25 | Regents Of The University Of Minnesota | Method for culturing human hematopoietic stem cells in vitro |
DE4219626A1 (de) * | 1992-06-16 | 1993-12-23 | Wehling Peter Priv Doz Dr Med | Methode zur Einschleusung therapeutisch relevanter Gene in Körperzellen |
ATE386800T1 (de) * | 1993-03-17 | 2008-03-15 | Us Gov Health & Human Serv | Immunogene chimäre umfassend nucleinsäuresequenzen, die signalsequenzpeptide des endoplasmatischen reticulums und mindestens ein anderes peptid codieren, deren verwendung in impfstoffen und zur behandlung von krankheiten |
US5543328A (en) * | 1993-08-13 | 1996-08-06 | Genetic Therapy, Inc. | Adenoviruses having modified fiber proteins |
AU5297496A (en) * | 1995-02-17 | 1996-09-04 | Government Of The United States Of America, As Represented By The Secretary Of The Department Of Health And Human Services, The | Methods of preparation and use of recombinant adenoviral vectors |
-
1993
- 1993-08-25 FR FR9310222A patent/FR2709309B1/fr not_active Expired - Fee Related
-
1994
- 1994-08-18 ZA ZA946264A patent/ZA946264B/xx unknown
- 1994-08-22 DE DE69433921T patent/DE69433921T2/de not_active Expired - Fee Related
- 1994-08-22 AT AT94925523T patent/ATE272117T1/de not_active IP Right Cessation
- 1994-08-22 JP JP50738795A patent/JP3731035B2/ja not_active Expired - Fee Related
- 1994-08-22 US US08/601,006 patent/US6210963B1/en not_active Expired - Fee Related
- 1994-08-22 CA CA002170159A patent/CA2170159A1/fr not_active Abandoned
- 1994-08-22 WO PCT/FR1994/001019 patent/WO1995006120A1/fr active IP Right Grant
- 1994-08-22 AU AU75398/94A patent/AU698043B2/en not_active Ceased
- 1994-08-22 KR KR1019960700928A patent/KR100392984B1/ko not_active IP Right Cessation
- 1994-08-22 EP EP94925523A patent/EP0719332B1/de not_active Expired - Lifetime
- 1994-08-23 IL IL11075494A patent/IL110754A/en not_active IP Right Cessation
-
1996
- 1996-02-23 NO NO19960743A patent/NO319990B1/no not_active IP Right Cessation
- 1996-02-23 FI FI960855A patent/FI960855A/fi not_active Application Discontinuation
Also Published As
Publication number | Publication date |
---|---|
NO960743D0 (no) | 1996-02-23 |
JP3731035B2 (ja) | 2006-01-05 |
IL110754A0 (en) | 1994-11-11 |
IL110754A (en) | 2001-04-30 |
KR100392984B1 (ko) | 2004-10-20 |
FR2709309B1 (fr) | 1995-11-10 |
US6210963B1 (en) | 2001-04-03 |
DE69433921T2 (de) | 2006-10-05 |
AU7539894A (en) | 1995-03-21 |
EP0719332B1 (de) | 2004-07-28 |
WO1995006120A1 (fr) | 1995-03-02 |
DE69433921D1 (de) | 2004-09-02 |
FR2709309A1 (fr) | 1995-03-03 |
NO960743L (no) | 1996-03-25 |
AU698043B2 (en) | 1998-10-22 |
CA2170159A1 (fr) | 1995-03-02 |
JPH09501837A (ja) | 1997-02-25 |
ZA946264B (en) | 1995-03-20 |
EP0719332A1 (de) | 1996-07-03 |
NO319990B1 (no) | 2005-10-10 |
FI960855A0 (fi) | 1996-02-23 |
FI960855A (fi) | 1996-04-23 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
ATE272117T1 (de) | Rekombinante zellen der monozyten-makrophagen zelllinie zur gen-therapie | |
Koi et al. | Tumor cell growth arrest caused by subchromosomal transferable DNA fragments from chromosome 11 | |
AR056723A2 (es) | Polipeptido purificado metodo para producirlo , metodo para identificarlo y/ o aislarlo composicion farmaceutica que lo comprende, secuencia de acidos nucleicos aislada que codifica dicho polipeptido, vector que contiene a dicha secuencia celula huesped transfectada por dicho vector, sonda nucleotid | |
DE69527540T2 (de) | Verwendung von stammzellenfaktor und löslichen interleukin-6-rezeptor zur vermehrung der hämatopoietischen vorläuferzellen | |
DE69837393D1 (de) | Stimulierung von hämatopoietischen zellen im vitro | |
ATE265219T1 (de) | Verwendung von cxcr4 antagonisten zur behandlung von krebs und autoimmunkrankheiten | |
UA66417C2 (en) | Recombinant adenovirus affecting canines, pharmaceutical composition | |
TR199801395A2 (xx) | Genetik olarak de�i�tirilmi� h�creler ve bunlar�n kullan�mlar�. | |
DE59903410D1 (de) | Hybridprotein zur hemmung der mastzelldegranulation und dessen verwendung | |
ATE361668T1 (de) | Kombinierte tumor suppressor-gen-therapie und chemotherapie bei der neoplasmabehandlung | |
DE69631972D1 (de) | Proliferationsinhibitor von endothellzellen und dessen verwendung | |
Facchetti et al. | Functional and molecular characterization of tumour-infiltrating lymphocytes and clones thereof from a major-histocompatibility-complex-negative human tumour: neuroblastoma | |
BR0010563A (pt) | Composições isoladas de células da pele e métodos para seu uso | |
DE69333954D1 (de) | An der streptogramin biosynthese beteiligte polypeptide, ihre kodierenden nukleotidsequenzen und ihre verwendung | |
DE69903559D1 (de) | Verwendung von neuen zelltod inducierenden mitteln im synergismus mit interferon | |
ES2144626T3 (es) | Uso de peptidos de adhesion celular para la modificacion del poder de adhesion de celulas eucarioticas entre si. | |
DE3855634D1 (de) | Innerhalb des alpha-Locus gelegenes T-Zell-Rezeptor-Gen und DNA-Konstruktionen | |
DE69328832D1 (de) | Zielelektrode zur verhinderung von korrision in elektrochemischen zellen | |
BR9407357A (pt) | Novos tripeptideos utilizáveis em terapia cns e imune | |
SE8605459D0 (sv) | Novel cell growth regulatory factor | |
Haughn | Tumor Cell Growth Arrest Caused by | |
AU1402495A (en) | Use of macrophage depleting agents for prolonging the survival of non-autologus hematopoietic cell transplants and animal model assay systems |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
RER | Ceased as to paragraph 5 lit. 3 law introducing patent treaties |